loading

Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie

pulisher
Jun 05, 2025

Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? - Yahoo Finance

Jun 05, 2025
pulisher
Jun 05, 2025

Merck gains U.S. patent office support in Keytruda dispute - MSN

Jun 05, 2025
pulisher
Jun 04, 2025

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga

Jun 04, 2025
pulisher
Jun 04, 2025

Merck (MRK) Gains Edge in Keytruda Patent Dispute - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Merck dispute with Halozyme over Keytruda injection to get another USPTO look - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline - Insider Monkey

Jun 04, 2025
pulisher
Jun 04, 2025

PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Merck granted review of Halozyme patent claims by PTAB - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme - Yahoo Finance

Jun 04, 2025
pulisher
Jun 03, 2025

Halozyme (HALO) Faces Patent Challenge as USPTO Institutes Revie - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Halozyme (HALO) Faces Patent Challenges Affecting Stock Outlook | HALO Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Here’s Why Halozyme Therapeutics (HALO) Rebounded in Q1 - Insider Monkey

Jun 03, 2025
pulisher
Jun 02, 2025

(HALO) Investment Report - news.stocktradersdaily.com

Jun 02, 2025
pulisher
May 31, 2025

H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN

May 31, 2025
pulisher
May 30, 2025

Halozyme to Participate at Upcoming Investor Conferences - Kilgore News Herald

May 30, 2025
pulisher
May 30, 2025

Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright - Defense World

May 30, 2025
pulisher
May 29, 2025

Halozyme Therapeutics (HALO): HC Wainwright & Co. Reiterates Buy Rating | HALO Stock News - GuruFocus

May 29, 2025
pulisher
May 29, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - Longview News-Journal

May 29, 2025
pulisher
May 29, 2025

Halozyme stock holds Buy rating, $72 target from H.C. Wainwright By Investing.com - Investing.com UK

May 29, 2025
pulisher
May 28, 2025

Halozyme to Participate at Upcoming Investor Conferences | HALO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Halozyme CEO Sets Two Major Healthcare Conference Appearances: Goldman Sachs and Benchmark - Stock Titan

May 28, 2025
pulisher
May 28, 2025

3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) - sharewise

May 28, 2025
pulisher
May 28, 2025

Bristol-Myers wins EU nod for Opdivo injectable developed with Halozyme - MSN

May 28, 2025
pulisher
May 28, 2025

Implied Volatility Surging for Halozyme Therapeutics Stock Options - The Globe and Mail

May 28, 2025
pulisher
May 28, 2025

Bristol Myers Squibb, Halozyme Get EC Approval for Subcutaneous Formulation of Opdivo - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE - Nasdaq

May 28, 2025
pulisher
May 28, 2025

Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications | HALO Stock News - GuruFocus

May 28, 2025
pulisher
May 28, 2025

Breakthrough: EU Approves 5-Minute Cancer Treatment Option Using Halozyme's Technology - Stock Titan

May 28, 2025
pulisher
May 28, 2025

High Growth Tech Stocks To Watch In The US May 2025 - Yahoo Finance

May 28, 2025
pulisher
May 28, 2025

New Strong Buy Stocks for May 28th - The Globe and Mail

May 28, 2025
pulisher
May 18, 2025

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Hold” by Brokerages - Defense World

May 18, 2025
pulisher
May 16, 2025

J&J, Halozyme cut at Leerink on price control risk for combo products - MSN

May 16, 2025
pulisher
May 16, 2025

Halozyme Therapeutics (NASDAQ:HALO) Cut to “Strong Sell” at Leerink Partnrs - Defense World

May 16, 2025
pulisher
May 15, 2025

Halozyme downgraded at Morgan Stanley on price control risk - MSN

May 15, 2025
pulisher
May 15, 2025

Morgan Stanley Downgrades Halozyme Therapeutics (BIT:1HALO) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Morgan Stanley Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Leerink Partners Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Leerink Partners Downgrades Halozyme Therapeutics (NASDAQ:HALO) to Underperform - Defense World

May 15, 2025
pulisher
May 14, 2025

Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concer - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Leerink Partners Downgrades Halozyme Therapeutics (BMV:HALO) - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Halozyme Therapeutics (HALO) Downgraded by Morgan Stanley | HALO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Halozyme, J&J slide as analyst cuts rating on CMS draft guidance - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Halozyme (HALO) Downgraded Amid Medicare Price Negotiation Conce - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Halozyme stock downgraded at Morgan Stanley (HALO:NASDAQ) - Seeking Alpha

May 14, 2025
pulisher
May 14, 2025

Halozyme Therapeutics downgraded by Morgan Stanley with a new price target - Quantisnow

May 14, 2025
pulisher
May 14, 2025

Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Halozyme stock holds $78 target despite Medicare concerns By Investing.com - Investing.com Canada

May 14, 2025
pulisher
May 14, 2025

Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concerns | HALO Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Halozyme stock holds $78 target despite Medicare concerns - Investing.com

May 14, 2025
pulisher
May 14, 2025

Morgan Stanley cuts Halozyme stock rating, lowers target By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) - MSN

May 14, 2025
$1.15
price up icon 1.30%
$584.68
price up icon 0.75%
$308.75
price up icon 1.19%
$37.33
price up icon 2.30%
$4.68
price down icon 3.35%
$492.00
price up icon 1.78%
Capitalizzazione:     |  Volume (24 ore):